Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP UP

Novo Nordisk · Phase 3 · Completed · Enrollment 1407

NCT05646706

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

88.738.3
≥5%
≥10%
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 7.2 mg88.7%n/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Placebo38.3%n/rn/rn/r

Not shown

  • Semaglutide 2.4 mg: endpoint not reported